Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy

Depression and Anxiety

Volumn 30, Issue 8, 2013, Pages 723-731

  Farrell, Lara J ^a   Waters, Allison M ^a   Boschen, Mark J ^a   Hattingh, Laetitia ^a,b   McConnell, Harry ^a   Milliner, Ella L ^a   Collings, Nigel ^a   Zimmer Gembeck, Melanie ^a   Shelton, Doug ^c   Ollendick, Thomas H ^d   Testa, Chris ^e   Storch, Eric A ^f  

^a GRIFFITH UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c QUEENSLAND HEALTH   (Australia)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^e Tugun Compounding Pharmacy   (Australia)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

CBT; d cycloserine; obsessive compulsive disorder; pediatric

Indexed keywords

CYCLOSERINE; PLACEBO;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; COMPULSION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD;

CBT; D-CYCLOSERINE; OBSESSIVE-COMPULSIVE DISORDER; PEDIATRIC;

ADOLESCENT; ANTIMETABOLITES; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEASIBILITY STUDIES; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; OBSESSIVE-COMPULSIVE DISORDER; PILOT PROJECTS; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84881479479     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22132     Document Type: Article

References (46)

1. Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder. JAMA 2004; 292: 1969-1976.
2. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009; 19: 629-635.
3. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
4. Walker DL, Davis M,. Involvement of N-methyl-D-aspartate (NMDA) receptors within the amygdala in short- versus long-term memory for fear conditioning as assessed with fear-potentiated startle. Behav Neurosci 2000; 114: 1019-1033.
5. Norberg MM, Krystal JH, Toin DF,. A meta-analysis of d -cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-1126.
6. Kalisch R, Holt B, Petrovic P, et al. The NMDA agonist d -cycloserine facilitates fear memory consolidation in humans. Cereb Cortex 2009; 19: 187-196.
7. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144.
8. Hofmann SG, Pollack MH, Otto, MW,. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev 2006; 12: 208-217.
9. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63: 544-549.
10. Otto MW, Tolin DF, Simon NM, et al. Efficacy of D-cycloserine for enhancing response to cognitive-behaviour therapy for panic disorder. Biol Psychiatry 2010; 67: 365-370.
11. Kushner MG, Won Kim S, Donahue C, et al. D-Cycloserine augmented exposure therapy for obsessive compulsive disorder. Biol Psychiatry 2007; 62: 835-838.
12. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int J Clin Psychopharmacol 2007; 22: 230-237.
13. Wilhelm S, Buhlmann U, Tolin DF, et al. D-cycloserine augmentation of behaviour therapy. Am J Psychiatry 2008; 165: 335-341.
14. Rothbaum BO,. Critical parameters for D-cycloserine enhancement of cognitive behavioural therapy for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 293-296.
15. Chasson GS, Buhlmann U, Tolin DF, et al. Need for speed: evaluating slopes of recovery in behavior therapy enhanced with D-cycloserine. Behav Res Ther 2010; 48: 675-679.
16. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2010; 68: 1073-1076.
17. Stevens J, Wang W, Fan L, et al. Parental attitudes toward children's use of antidepressants and psychotherapy. J Child Adolesc Psychopharmaco 2009; 19: 289-296.
18. Scahill L, Riddle MA, McSwiggan-Hardin MT, et al. The Children's Yale-Brown Obsessive-Compulsive Scale: preliminary report of reliability and validity. JAACAP 1997; 36: 844-853.
19. Schulz KF, Altman DG, Moher D, For the CONSORT group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Open Med 2010; 4: 60-68.
20. Moher D, Hopewell S, Schulz KF, et al. For the CONSORT Group. CONSORT 2010. Explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 2010; 340: c869.
21. Silverman WK, Albano AM,. Anxiety Disorders Interview Schedule for DSM-IV: Parent Version. San Antonio, TX: Graywing; 1996.
22. Silverman WK, Eisen AR,. Age differences in the reliability of parent and child reports of child anxious symptomatology using a structured interview. JAACAP 1992; 31: 117-124.
23. Barrett P, Dadds MR, Rapee RM,. Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol 1996; 64: 333-342.
24. Kendall PC,. Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol 1994; 62: 100-110.
25. Albano A, Knox L, Barlow D,. Parental involvement in the treatment of childhood obsessive-compulsive disorder: a multiple-baseline examination incorporating parents. Behav Ther 1996; 27: 93-115.
26. Waters T, Barrett P, March J,. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: an open clinical trial. A J Psychother 2001; 55, 372-387.
27. Insel TR, Hoover C, Murphy DL,. Parents of patients with obsessive-compulsive disorder. Psychol Med 1983; 13: 807-811.
28. Kim S, Dysken M, Kuskowski N,. The symptom checklist-90 obsessive compulsive subscale: a reliability and validity study. Psychiatry Res 1992; 41: 37-44.
29. Kim S, Dysken M, Kuskowski N, Hoover K,. The Yale-Brown Obsessive-Compulsive-Scale and the NIMH Global Obsessive-Compulsive Scale (GOCS): a reliability and validity study. Intern J of Meth in Psych Res 1993; 3: 37-44.
30. Taylor S,. Assessment of obsessive-compulsive disorder. In:, Swinson R, Antony M, editors. Obsessive Compulsive Disorder: Theory, Research, and Treatment. New York: Guilford; 1998: 229-257.
31. Storch EA, Murphy T, Adkins J, et al. The Children's Yale-Brown Obsessive-Compulsive Scale: psychometric properties of child- and parent-report formats. J Anx Dis 2006; 20: 1055-1070.
32. March JS,. Multidimensional Anxiety Scale for Children. North Tonawanda, NY: Multi-Health Systems. 1997.
33. March JS, Parker JDA, Sullivan K, Stallings P, Conners K,. The multidimensional anxiety scale for children (MASC): factor structure, reliability and validity. JAACAP 1997; 36: 554-565.
34. World Health Organization (WHO). Summary of Product Characteristics, Cycloserine 250 mg. Geneva: World Health Organization; 2007.
35. Farrell LJ, Waters AM,. OCD Busters: A Cognitive-Behavioural Treatment Program. Unpublished Manuscript. Griffith University; 2008.
36. March J, Mulle K,. OCD in Children and Adolescents: A Cognitive-Behavioral Treatment Manual. New York: Guilford Press; 1998.
37. March J, Mulle K, Herbel B,. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol driven treatment package. JAACAP 1994; 33: 333-341.
38. Cohen J,. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum. 1988.
39. Storch EA, Lewin AB, De Nadai AS, et al. Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. JAACAP 2010: 49: 708-717.
40. Jacobson NS, Truax P,. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-19.
41. Jacobson NS, Roberts LJ, Berns SB, et al. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol 1999; 67: 300-307.
42. Jacobson NS, Follette WC, Revenstorf D,. Psychotherapy outcome research: methods for reporting variability and evaluating clinical significance. Behav Ther 1984; 15: 336-352.
43. Barrett PM, Healy-Farrell LJ, March JS,. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. JAACAP 2004; 43: 46-62.
44. Bouton ME, Vurbic D, Woods, AM,. D-cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem 2008; 90: 504-510.
45. Smits JAJ, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry; 2013. Available at: http://dx.doi.org/ 10.1016/j.biopsych.2012.12.009.
46. Leon AC, Davis LL, Kraemer HC,. The role and interpretation of pilot studies in clinical research. J Psychiatr Res 2011; 45: 626-629.